Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14263051 | 1.00 | AR (0.54) | ARALDH1A1MAPTMMP2PPARA | |
| SCHEMBL13520469 | 1.00 | AR (0.54) | ARALDH1A1MAPTMMP2PPARA | |
| SCHEMBL13574311 | 0.87 | AR (0.54) | ARALDH1A1MAPTMMP2RAB9A | |
| SCHEMBL18677477 | 0.86 | AR (0.53) | ARALDH1A1MAPTMMP2RAB9A | |
| SCHEMBL14933773 | 0.86 | AR (0.54) | ARALDH1A1MAPTMMP2RAB9A | |
| SCHEMBL18677371 | 0.86 | AR (0.53) | ARALDH1A1MAPTMMP2RAB9A | |
| SCHEMBL17643998 | 0.86 | AR (0.53) | ARALDH1A1MAPTMMP2RAB9A | |
| SCHEMBL4279128 | 0.86 | AR (0.54) | ARALDH1A1MAPTMMP2RAB9A | |
| SCHEMBL13523302 | 0.84 | AR (0.52) | ARALDH1A1MAPTMMP2RAB9A | |
| SCHEMBL10062799 | 0.84 | AR (0.55) | ARALDH1A1MAPTMMP2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3147278-B1 | COMPOUND FOR TREATING BREAST CANCER AND PROGESTIN-DEPENDENT CONDITIONS | UNIV TENNESSEE RES FOUND (US) | 2020-02-12 | — | — | EP | disclosed |
| US-20180071242-A1 | SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2018-03-15 | — | — | US | disclosed |
| EP-3147278-A1 | COMPOUND FOR TREATING BREAST CANCER AND PROGESTIN-DEPENDENT CONDITIONS | University of Tennessee Research Foundation (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20160089356-A1 | SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2016-03-31 | — | — | US | disclosed |
| US-8003689-B2 | Metabolites of selective androgen receptor modulators and methods of use thereof | GTX, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003689-B2 | Metabolites of selective androgen receptor modulators and methods of use thereof | GTX, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100004326-A1 | METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | ONCTERNAL THERAPEUTICS, INC | 2010-01-07 | — | — | US | disclosed |
| US-20100004326-A1 | METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | ONCTERNAL THERAPEUTICS, INC | 2010-01-07 | — | — | US | disclosed |
| WO-2009155481-A1 | METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | GTX, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004326-A1 | METABOLITES OF SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | AR, SHBG, GPR119 | AR 1/4885ALDH1A1 777/4885MAPT 2968/4885 |
| US-20180071242-A1 | SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF | CPT1B, MTPN, MUSK | AR 1366/4885ALDH1A1 754/4885MAPT 4229/4885 |
| US-20160089356-A1 | SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF | CPT1B, MTPN, MUSK | AR 1366/4885ALDH1A1 754/4885MAPT 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.